GSK’s Approach to responding to COVID-19

To help people do more, feel better, live longer

People

Business Continuity

Solutions
GSK pursuing solutions based on four principles

Solutions

Using our science, technology, portfolio and resources to support development of products for prevention and treatment of COVID-19 and the overall global response

- Working in Partnership
- Global approach
- Commitment to Access
- Pandemic preparedness
GSK adjuvant-based vaccine collaborations

Collaboration approach:
- To explore potential development of adjuvanted COVID-19 vaccines
- To support development of best vaccines in fastest way possible
- GSK adjuvant technology proven in pandemic influenza H1N1:
  - less antigen needed
  - more vaccine doses made
- Data from different collaborations expected in next few months

Does not include Vir vaccine collaboration and additional collaborations not yet disclosed
Key role of adjuvanted vaccine in pandemic response

An antigen stimulates an immune response and produces antibodies.

These antibodies help protect the person from the infection.

An adjuvant can be added to the vaccine to boost this immune response.

Which means less antigen is needed.

This is particularly important during a pandemic as more vaccine doses can be available to protect more people around the world.
GSK and Sanofi in unprecedented collaboration to develop adjuvanted COVID-19 vaccine

• Two of the world’s biggest vaccine companies
• Proven technologies
• Ability to manufacture at scale
• Long history of commitment to access

Adjuvanted COVID-19 vaccine:
• Phase I clinical trials to start in H2 2020
• If successful and subject to regulatory considerations, companies aim to make adjuvanted vaccine available by H2 2021
Committed to availability, access and investing in global long-term pandemic preparedness

We do not expect to profit from the portfolio of COVID-19 vaccines collaborations during the pandemic:

- We will responsibly price our adjuvant
- We will make our adjuvant available to the world’s poorest countries, including through donations
- Any short-term profit we generate will be invested in support of coronavirus-related research & global long-term pandemic preparedness- either through GSK internal investments or with external partners
- Our approach is responsive to COVID-19 and supports a sustainable industry model
Collaboration with Vir Biotechnology to identify new solutions for coronaviruses*

- Vir Biotechnology’s monoclonal antibody platform has proven success in identifying and developing antibodies as treatments for multiple pathogens
- Highly complementary to GSK’s R&D focus on the science of immunology

- **First priority**: accelerate VIR-7831 and VIR-7832, two promising COVID-19 antibody candidates, into Phase II clinical trials in next 3 - 5 months
- **Longer term**: screen for novel therapeutic or preventative options for future coronavirus outbreaks

*Vir collaboration is subject to regulatory clearance*
Therapeutics approach

Anti-viral medicines
Selected GSK & Viiv assets progressed to in-vitro testing against the COVID-19 virus

Prevention or treatment of secondary complications
Short-list of clinical-stage assets being reviewed for potential utility in COVID-19

Underpinned by GSK participation in global collaborative models
e.g. COVID-19 Therapeutics Accelerator, FNIH Rapid Response, Transcelerate, Pharma R&D Leaders Collaboration
Investing in global long-term pandemic preparedness

- Rapid response and scale up plans
- Regulatory support
- Research and Development
- Manufacturing capacity
- Testing and Diagnostics
- Pandemic leadership organisations

Internal investments
OR
External partners
## GSK global and local community support

### Donations

- **$10m donation** to WHO COVID-19 Solidarity Response Fund
- **Over £1.6m** donated to support our local communities to date
- **Donation of Consumer Health products** to 10 countries to date
- **NHS Charities Together COVID Appeal** UK employee fundraising

### Diagnostic testing

- **A new COVID-19 diagnosis lab**
  - In collaboration with AZ and Cambridge University to support UK testing

### Equipment and in kind

- **Over 300,000 units of PPE** donated globally
- **New volunteering policies** have seen employees volunteer as frontline health workers, supporting diagnostic testing and in non-specialist capacities

### Diagnostic testing

- **In Belgium**, GSK labs will test up to at least 6,000 samples per day